Cephalexin

Pharmacologic Category

Antibiotic, Cephalosporin (First Generation)

Dosing: Adult

Usual dosage range: Oral: 250 to 1,000 mg every 6 hours or 500 mg every 12 hours (maximum: 4 g/day).

Indication-specific dosing:

Cellulitis (nonpurulent)/erysipelas, mild (alternative agent): Oral: 500 mg 4 times daily for at least 5 days (duration should be extended if not resolved/slow response) (IDSA [Stevens 2014]).

Endocarditis, prophylaxis (dental or invasive respiratory tract procedures) (alternative agent) (off-label use): Oral: 2 g 30 to 60 minutes prior to procedure. Note: AHA guidelines recommend prophylaxis only in patients undergoing invasive procedures and in whom underlying cardiac conditions may predispose to a higher risk of adverse outcomes should infection occur (AHA [Wilson 2007]).

Impetigo or ecthyma: Oral: 250 to 500 mg 4 times daily for 7 days. Note: Not an appropriate agent if MRSA is suspected or confirmed (Baddour 2019; IDSA [Stevens 2014]).

Prosthetic joint infection (off-label use): Oral: Treatment (following pathogen-specific IV therapy in patients undergoing 1-stage exchange or debridement with retention of prosthesis). Note: Duration ranges from a minimum of 3 months to indefinitely, depending on patient-specific factors (Berbari 2019):

Staphylococci (methicillin-susceptible): 500 mg every 6 to 8 hours or 1 g every 8 to 12 hours. For the first 3 to 6 months of therapy, combine with rifampin (Berbari 2019; IDSA [Osmon 2013]).

Streptococci, beta-hemolytic (alternative agent): 500 mg every 6 to 8 hours (Berbari 2019; IDSA [Osmon 2013]).

Cutibacterium spp (alternative agent): 500 mg every 6 to 8 hours (IDSA [Osmon 2013]; Kanafani 2019).

Streptococcal pharyngitis (group A) (alternative agent for mild [non-anaphylactic] penicillin allergy): Oral: 500 mg every 12 hours for 10 days (IDSA [Shulman 2012]; Pichichero 2020; manufacturer's labeling).

Urinary tract infection:

Acute uncomplicated or simple cystitis, treatment (alternative agent): Oral: 250 to 500 mg every 6 hours for 5 to 7 days (Bolding 1978; Hooton 2019a; Hooton 2019b; Johnson 1972; Menday 2000).

Bacteriuria (≥10⁵ CFU per mL), asymptomatic, in pregnancy: Oral: 250 to 500 mg every 6 hours for 4 to 7 days (ACOG 782 2019; Hooton 2019c; IDSA [Nicolle 2019]; Pedler 1985).

Cystitis, uncomplicated, prophylaxis for recurrent infection (off-label use):

Note: Prophylaxis may be considered in nonpregnant women with bothersome, recurrent uncomplicated cystitis despite nonantimicrobial preventative measures. The optimal duration of prophylaxis has not been established; duration ranges from 3 to 12 months, with periodic assessment and monitoring (AUA/CUA/SUFU [Anger 2019]; Hooton 2019d).

Continuous prophylaxis: Oral: 125 to 250 mg once daily (AUA/CUA/SUFU [Anger 2019]; Gower 1975).

Postcoital prophylaxis: Females with cystitis temporally related to sexual intercourse: Oral: 250 mg as a single dose immediately before or after sexual intercourse (AUA/CUA/SUFU [Anger 2019]; Pfau 1992).

* See Dosage and Administration in AHFS Essentials for additional information.

Dosing: Geriatric

Refer to adult dosing.

Dosing: Renal Impairment: Adult

CrCl ≥60 mL/minute: No dosage adjustment necessary.

CrCl 30 to 59 mL/minute: There are no specific dosage adjustments provided in the manufacturer's labeling; maximum recommended daily dose: 1,000 mg/day.

CrCl 15 to 29 mL/minute: 250 mg every 8 to 12 hours

CrCl 5 to 14 mL/minute (not yet on dialysis): 250 every 24 hours

CrCl 1 to 4 mL/minute (not yet on dialysis): 250 mg every 48 to 60 hours

End-stage renal disease (on intermittent hemodialysis: There are no dosage adjustments provided in the manufacturer's labeling; however, the following guidelines have been used by some clinicians (Aronoff 2007): Oral: 250 to 500 mg every 12 to 24 hours; moderately dialyzable (20% to 50%); give dose after dialysis session.

Peritoneal dialysis: There are no dosage adjustments provided in the manufacturer's labeling; however, the following guidelines have been used by some clinicians (Aronoff 2007): Oral: 250 to 500 mg every 12 to 24 hours.

Dosing: Hepatic Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Pediatric

General dosing, susceptible infection (Bradley 2019; Red Book [AAP 2018]): Infants, Children, and Adolescents:

Mild to moderate infection: Oral: 25 to 50 mg/kg/day divided every 6 or 12 hours; maximum daily dose: 2,000 mg/day.

Severe infection (eg, bone and joint infections): Oral: 75 to 100 mg/kg/day divided every 6 to 8 hours; maximum daily dose: 4,000 mg/day.

Catheter (peritoneal dialysis); exit-site or tunnel infection: Limited data available: Infants, Children, and Adolescents: Oral: 10 to 20 mg/kg/day once daily or divided into 2 doses; maximum dose: 1,000 mg/dose (ISPD [Warady 2012]).

Pharyngitis/tonsillitis (group A streptococcal): Note: Use is reserved for patients with penicillin allergy (non-anaphylactic) (IDSA [Shulman 2012]).

Infants, Children, and Adolescents: Oral: 40 mg/kg/day divided every 12 hours for 10 days, maximum dose: 500 mg/dose (IDSA [Shulman 2012]).

Impetigo (staphylococcus or streptococcus): Note: Do not use if MRSA is suspected or confirmed.

Infants, Children, and Adolescents: Oral: 25 to 50 mg/kg/day divided every 6 or 8 hours; some experts suggest up to 75 mg/kg/day divided every 8 hours may be necessary in some cases; maximum daily dose: 1,000 mg/day; continue for at least 7 days, full duration dependent upon clinical response (Bradley 2019; IDSA [Stevens 2014]).

Otitis media, acute (AOM): Note: Cephalexin is not routinely recommended as an empiric treatment option (AAP [Lieberthal 2013]).

Children >1 year and Adolescents <15 years: Oral: 75 to 100 mg/kg/day divided every 6 hours; maximum dose not established for AOM; usual maximum adult dose for mild to moderate infections: 500 mg/dose and for severe infections: 1,000 mg/dose.

Skin and skin structure infections (eg, cellulitis, erysipelas): Infants, Children, and Adolescents: Oral: 25 to 50 mg/kg/day divided every 6 hours; maximum dose: 500 mg/dose; continue for at least 5 days or longer depending upon clinical response (IDSA [Stevens 2014]).

Endocarditis prophylaxis: Note: AHA guidelines (Baltimore 2015) limit the use of prophylactic antibiotics to patients at the highest risk for infective endocarditis (IE) or adverse outcomes (eg, prosthetic heart valves, patients with previous IE, unrepaired cyanotic congenital heart disease, repaired congenital heart disease with prosthetic material or device during first 6 months after procedure, repaired congenital heart disease with residual defects at the site or adjacent to site of prosthetic patch or device, and heart transplant recipients with cardiac valvulopathy):

Dental or oral procedures, or respiratory tract procedures (eg, tonsillectomy, adenoidectomy): Note: Recommended for use in patients with penicillin allergy (non-anaphylactic):

Infants, Children, and Adolescents: Oral: 50 mg/kg administered 30 to 60 minutes prior to procedure; maximum dose: 2,000 mg/dose (AHA [Wilson 2007]).

Pneumonia, community-acquired: S. aureus (methicillin-susceptible), mild infection or step-down therapy: Infants >3 months, Children, and Adolescents: Oral: 75 to 100 mg/kg/day in 3 to 4 divided doses (IDSA/PIDS [Bradley 2011]); maximum daily dose: 4,000 mg/day (Red Book [AAP 2018]).

Urinary tract infection:

Empiric therapy in febrile patients: Infants ≥2 months and Children <24 months: Oral: 50 to 100 mg/kg/day divided every 6 hours for 7 to 14 days (AAP 2011).

Treatment:

Children and Adolescents <15 years: Oral: 25 to 50 mg/kg/day divided every 6 to 12 hours for 7 to 14 days, maximum dose: 500 mg/dose; for severe infections, 50 to 100 mg/kg/day divided every 6 to 12 hours may be necessary; maximum daily dose: 4,000 mg/day.

Adolescents ≥15 years: Oral: 250 mg every 6 hours or 500 mg every 12 hours for 7 to 14 days; higher doses may be necessary for severe infections; maximum daily dose: 4,000 mg/day.

Osteoarticular infection (eg, septic arthritis, osteomyelitis); step-down therapy: Infants, Children, and Adolescents: Oral: 100 mg/kg/day divided every 6 to 8 hours; maximum daily dose: 4,000 mg/day; duration of therapy variable, dependent upon clinical response and typically extensive (weeks of therapy); compliance should be monitored (Bradley 2019; Red Book [AAP 2018]); a small (n=11) prospective, open-label pharmacokinetic study reported a median dose of 40 mg/kg/dose every 8 hours (mean age: 7 years; range: 1 to 16 years; dose range: 19 to 51 mg/kg/dose every 8 hours) maintained serum concentrations long enough to meet the pharmacokinetic/pharmacodynamic target for efficacy (T>MIC ≥ 40%) (Autmizguine 2013).

Dosing: Renal Impairment: Pediatric

Weight-based dosing: Infants, Children, and Adolescents: There are no recommendations in the manufacturer's labeling; the following adjustments have been recommended (Aronoff 2007). Note: Renally-adjusted dose recommendations are based on doses of 25 to 50 mg/kg/day divided every 6 hours: Oral:

CrCl >50 mL/minute/1.73 m²: No adjustment necessary.

CrCl 30 to 50 mL/minute/1.73 m²: 5 to 10 mg/kg/dose every 8 hours (maximum dose: 500 mg/dose).

CrCl 10 to 29 mL/minute/1.73 m²: 5 to 10 mg/kg/dose every 12 hours (maximum dose: 500 mg/dose).

CrCl <10 mL/minute/1.73 m²: 5 to 10 mg/kg/dose every 24 hours (maximum dose: 500 mg/dose).

Intermittent hemodialysis: 5 to 10 mg/kg/dose every 24 hours after dialysis (maximum dose: 500 mg/dose).

Peritoneal dialysis: 5 to 10 mg/kg/dose every 24 hours (maximum dose: 500 mg/dose).

Fixed dosing: Adolescents ≥15 years: Oral:

CrCl ≥60 mL/minute: No dosage adjustment necessary.

CrCl 30 to 59 mL/minute: No adjustment necessary; maximum recommended daily dose: 1,000 mg/day.

CrCl 15 to 29 mL/minute: 250 mg every 8 to 12 hours.

CrCl 5 to 14 mL/minute (not yet on dialysis): 250 every 24 hours.

CrCl 1 to 4 mL/minute (not yet on dialysis): 250 mg every 48 to 60 hours.

Dosing: Hepatic Impairment: Pediatric

There are no dosing adjustments provided in the manufacturer's labeling.

Calculations

Use: Labeled Indications

Bone infections: Treatment of bone infections caused by Staphylococcus aureus and/or Proteus mirabilis.

Genitourinary tract infections: Treatment of genitourinary tract infections, including acute prostatitis, caused by Escherichia coli, P. mirabilis, and Klebsiella pneumoniae.

Otitis media: Treatment of otitis media caused by Streptococcus pneumoniae, Haemophilus influenzae, S. aureus, Streptococcus pyogenes, and Moraxella catarrhalis.

Respiratory tract infections: Treatment of respiratory tract infections (including pharyngitis) caused by S. pneumoniae and S. pyogenes.

Skin and skin structure infections: Treatment of skin and skin structure infections caused by S. aureus and/or S. pyogenes.

* See Uses in AHFS Essentials for additional information.

Use: Off-Label: Adult

Cystitis, uncomplicated, prophylaxis for recurrent infectionLevel of Evidence [C, G]

Data from a limited number of patients studied suggest that continuous or postcoital cephalexin may be beneficial in the prophylaxis of recurrent uncomplicated cystitis in pregnant and non-pregnant patients ^Ref.

Based on the American Urological Association/Canadian Urological Association/Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction guidelines for recurrent uncomplicated urinary tract infections in women, cephalexin is effective and recommended for prophylaxis (continuous or intermittent [postcoital] use) of recurrent uncomplicated cystitis in nonpregnant women ^Ref.

Endocarditis, prophylaxisLevel of Evidence [G]

Based on the American Heart Association (AHA) guidelines for the prevention of infective endocarditis, cephalexin is an effective and recommended alternative agent for prophylaxis against infective endocarditis in patients with certain cardiac conditions who are undergoing dental or respiratory tract procedures and are allergic to penicillins or ampicillin. Note: Cephalexin should not be used in patients with a history of anaphylaxis, angioedema, or urticaria with penicillins or ampicillin.

Prosthetic joint infectionLevel of Evidence [G]

Based on the Infectious Diseases Society of America (IDSA) guidelines for the management of prosthetic joint infection, cephalexin is an effective and recommended agent for treatment (following pathogen-specific IV therapy in patients undergoing 1-stage exchange or debridement with retention of prosthesis) and long-term oral antimicrobial suppression of prosthetic joint infection caused by staphylococci (methicillin-susceptible) (for the first 3 to 6 months of therapy, in combination with rifampin), and an effective and recommended alternative agent when this condition is caused by beta-hemolytic streptococci or Cutibacterium species.

Level of Evidence Definitions

Level of Evidence Scale

Class and Related Monographs

Cephalosporins

Clinical Practice Guidelines

Acne:

American Academy of Dermatology, "Guidelines of care for the management of acne vulgaris," May 2016

Diabetic Foot Infection:

IDSA, “The Diagnosis and Treatment of Diabetic Foot Infections,” 2012

Infective Endocarditis:

“AHA 2007 Guidelines for the Prevention of Infective Endocarditis,” April 2007

Pharyngitis, Group A Streptococci:

IDSA, “Clinical Practice Guideline for the Diagnosis and Management of Group A Streptococcal Pharyngitis,” September 2012

Pneumonia, Community-Acquired:

IDSA/PIDS, "The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age," 2011

Prosthetic Joint Infection:

IDSA, “Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guideline,” January 2013

Skin and Soft-tissue Infection:

IDSA, “Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections,” June 2014.

Urinary Tract Infections:

AUA/CUA/SUFU, "Recurrent Uncomplicated Urinary Tract Infections in Women," May 2019

IDSA, "Clinical Practice Guidelines for the Management of Asymptomatic Bacteriuria," May 2019

IDSA, “International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women,” March 2011

Administration: Oral

Administer without regard to food. If GI distress, take with food. Give around-the-clock to promote less variation in peak and trough serum levels.

Administration: Pediatric

Oral: Administer without regard to food. If GI distress, may take with food. Give around-the-clock to promote less variation in peak and trough serum levels.

Oral suspension: Shake suspension well before use. Administer with an accurate measuring device; do not use a household teaspoon (overdosage may occur).

Storage/Stability

Capsule: Store at 25°C (77°F); excursions permitted to 15ºC to 30ºC (59ºF to 86ºF).

Powder for oral suspension: Store at 20°C to 25°C (68°F to 77°F). Refrigerate after reconstitution; discard after 14 days.

Tablet: Store at 20°C to 25°C (68°F to 77°F).

Preparation for Administration: Pediatric

Oral: Powder for oral suspension: Reconstitute powder for oral suspension with appropriate amount of water as specified on the bottle. Shake vigorously until suspended.

Medication Patient Education with HCAHPS Considerations

What is this drug used for?

• It is used to treat bacterial infections.

Frequently reported side effects of this drug

• Nausea

• Vomiting

• Abdominal pain

• Diarrhea

Other side effects of this drug: Talk with your doctor right away if you have any of these signs of:

• Liver problems like dark urine, fatigue, lack of appetite, nausea, abdominal pain, light-colored stools, vomiting, or yellow skin.

• Bruising

• Bleeding

• Chills

• Sore throat

• Severe loss of strength and energy

• Confusion

• Sensing things that seem real but are not

• Unable to pass urine

• Change in amount of urine passed

• Seizures

• Severe dizziness

• Severe headache

• Severe joint pain

• Vaginal pain, itching, and discharge

• Stevens-Johnson syndrome/toxic epidermal necrolysis like red, swollen, blistered, or peeling skin (with or without fever); red or irritated eyes; or sores in mouth, throat, nose, or eyes.

• Clostridioides (formerly Clostridium) difficile-associated diarrhea like abdominal pain or cramps, severe diarrhea or watery stools, or bloody stools.

• Signs of a significant reaction like wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat.

Note: This is not a comprehensive list of all side effects. Talk to your doctor if you have questions.

Consumer Information Use and Disclaimer: This information should not be used to decide whether or not to take this medicine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about this medicine. It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not specific medical advice and does not replace information you receive from the healthcare provider. You must talk with the healthcare provider for complete information about the risks and benefits of using this medicine.

Medication Safety Issues

Sound-alike/look-alike issues:

Contraindications

Hypersensitivity to cephalexin, other cephalosporins, or any component of the formulation

Warnings/Precautions

Concerns related to adverse effects:

• Hypersensitivity: Allergic reactions (eg, rash, urticaria, angioedema, anaphylaxis, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis [TEN]) have been reported. If an allergic reaction occurs, discontinue immediately and institute appropriate treatment.

• Elevated INR: May be associated with increased INR, especially in nutritionally-deficient patients, prolonged treatment, hepatic or renal disease.

• Penicillin allergy: Use with caution in patients with a history of penicillin allergy, especially IgE-mediated reactions (eg, anaphylaxis, angioedema, urticaria).

• Seizure disorder: Use with caution in patients with a history of seizure disorder; high levels, particularly in the presence of renal impairment, may increase risk of seizures.

• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including C. difficile-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed >2 months post antibiotic treatment.

Disease-related concerns:

• Renal impairment: Use with caution in patients with renal impairment; modify dosage in severe impairment.

Concurrent drug therapy issues:

• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.

Other warnings/precautions:

• Direct Coombs tests: Positive direct Coombs tests and acute intravascular hemolysis has been reported. If anemia develops during or after therapy, discontinue use and work up for drug-induced hemolytic anemia.

* See Cautions in AHFS Essentials for additional information.

Geriatric Considerations

Adjust dose for renal function.

Pregnancy Considerations

Cephalexin crosses the placenta and produces therapeutic concentrations in the fetal circulation and amniotic fluid (Creatsas 1980).

An increased risk of major birth defects or other adverse fetal or maternal outcomes has generally not been observed following use of cephalosporin antibiotics, including cephalexin, during pregnancy.

Peak concentrations in pregnant patients are similar to those in nonpregnant patients. Prolonged labor may decrease oral absorption (Griffith 1983; Paterson 1972). Cephalexin may be used in certain situations prior to vaginal delivery in females at high risk for endocarditis, and use may be considered for postcesarean delivery prophylaxis in obese females (ACOG 199 2018). Use of cephalexin may also be considered for the treatment of asymptomatic bacteriuria in pregnant women (Nicolle [IDSA 2019]).

Breast-Feeding Considerations

Cephalexin is present in breast milk.

The relative infant dose (RID) of cephalexin is 0.13% to 0.52% when compared to an infant therapeutic dose of 25 to 100 mg/kg/day.

In general, breastfeeding is considered acceptable when the relative infant dose is <10% (Anderson 2016; Ito 2000).

The RID of cephalexin was calculated using a milk concentration of 0.85 mcg/mL, providing an estimated daily infant dose via breast milk of 0.13 mg/kg/day. This milk concentration was obtained following a single maternal dose of cephalexin 1,000 mg orally on the third postpartum day. The mean peak milk concentration occurred 4 to 5 hours after the dose (Kafetzis 1981). Slightly higher concentrations of cephalexin were detected in the breast milk of a breastfeeding woman also administered probenecid and cephalexin for ≥16 days (Ilett 2006).

Diarrhea has been reported in breastfeeding infants (Ilett 2006; Ito 1993). In general, antibiotics that are present in breast milk may cause non-dose-related modification of bowel flora. Monitor infants for GI disturbances (WHO 2002).

When an antibiotic is needed, cephalexin may be used to treat mastitis in breastfeeding women allergic to preferred agents (Amir 2014; Berens 2015). According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother

Lexicomp Pregnancy & Lactation, In-Depth

Cephalexin

Briggs' Drugs in Pregnancy & Lactation

Cephalexin

Adverse Reactions

Frequency not defined.

Central nervous system: Agitation, confusion, dizziness, fatigue, hallucination, headache

Dermatologic: Erythema multiforme (rare), genital pruritus, skin rash, Stevens-Johnson syndrome (rare), toxic epidermal necrolysis (rare), urticaria

Gastrointestinal: Abdominal pain, diarrhea, dyspepsia, gastritis, nausea (rare), pseudomembranous colitis, vomiting (rare)

Genitourinary: Genital candidiasis, vaginal discharge, vaginitis

Hematologic & oncologic: Eosinophilia, hemolytic anemia, neutropenia, thrombocytopenia

Hepatic: Cholestatic jaundice (rare), hepatitis (transient, rare), increased serum ALT, increased serum AST

Hypersensitivity: Anaphylaxis, angioedema, hypersensitivity reaction

Neuromuscular & skeletal: Arthralgia, arthritis, arthropathy

Renal: Interstitial nephritis (rare)

* See Cautions in AHFS Essentials for additional information.

Allergy and Idiosyncratic Reactions

Cephalosporin Allergy

Metabolism/Transport Effects

None known.

Drug Interactions Open Interactions

BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). Risk X: Avoid combination

BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). Risk C: Monitor therapy

Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics. Risk X: Avoid combination

Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. Risk C: Monitor therapy

MetFORMIN: Cephalexin may increase the serum concentration of MetFORMIN. Risk C: Monitor therapy

Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Cephalexin. Specifically, the zinc contained in many multivitamins may decrease cephalexin absorption. Management: Consider administering multivitamins at least 3 hours after cephalexin. Risk D: Consider therapy modification

Multivitamins/Minerals (with AE, No Iron): May decrease the serum concentration of Cephalexin. Specifically, the zinc contained in many multivitamins may decrease cephalexin absorption. Management: Consider administering multivitamins at least 3 hours after cephalexin. Risk D: Consider therapy modification

Probenecid: May increase the serum concentration of Cephalosporins. Risk C: Monitor therapy

Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate. Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic. Risk D: Consider therapy modification

Sucroferric Oxyhydroxide: May decrease the serum concentration of Cephalexin. Management: Administer cephalexin at least 1 hour before administration of sucroferric oxyhydroxide. Risk D: Consider therapy modification

Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected. Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents. Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents. Risk D: Consider therapy modification

Vitamin K Antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists. Risk C: Monitor therapy

Zinc Salts: May decrease the absorption of Cephalexin. Management: Consider administering oral zinc salts at least 3 hours after cephalexin. Exceptions: Zinc Chloride. Risk D: Consider therapy modification

Food Interactions

Peak antibiotic serum concentration is lowered and delayed, but total drug absorbed is not affected. Cephalexin serum levels may be decreased if taken with food. Management: Administer without regard to food.

Test Interactions

Positive direct Coombs', false-positive urinary glucose test using cupric sulfate (Benedict's solution, Clinitest®, Fehling's solution), false-positive serum or urine creatinine with Jaffé reaction, false-positive urinary proteins and steroids

Monitoring Parameters

With prolonged therapy monitor renal, hepatic, and hematologic function periodically; monitor for signs of anaphylaxis during first dose

Advanced Practitioners Physical Assessment/Monitoring

Assess results of culture/sensitivity tests and patient's allergy history prior to therapy. Obtain CBC, renal function tests, liver function tests periodically with prolonged therapy. Monitor for signs of anaphylaxis during first dose. Advise patients with diabetes about use of Clinitest (may cause false-positive test). Assess for effectiveness of treatment. Test for C.difficile if patient develops diarrhea.

Nursing Physical Assessment/Monitoring

Check labs results and report abnormalities. Monitor closely for signs of hypersensitivity (shortness-of-breath, dyspnea, chest pain, complaints of difficulty swallowing or throat tightness, or change in vital signs). Monitor for severe or bloody diarrhea and send a specimen to the lab for C.difficile. Monitor for improvement with infection. Advise patients with diabetes about use of Clinitest (may cause false-positive test). Teach patient to report opportunistic infection and hypersensitivity reaction.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Capsule, Oral:

Daxbia: 333 mg [DSC] [contains brilliant blue fcf (fd&c blue #1), fd&c yellow #10 (quinoline yellow), fd&c yellow #6 (sunset yellow)]

Keflex: 250 mg, 500 mg, 750 mg [contains brilliant blue fcf (fd&c blue #1), fd&c yellow #10 (quinoline yellow), fd&c yellow #6 (sunset yellow)]

Generic: 250 mg, 500 mg, 750 mg

Suspension Reconstituted, Oral:

Generic: 125 mg/5 mL (100 mL, 200 mL); 250 mg/5 mL (100 mL, 200 mL)

Tablet, Oral:

Generic: 250 mg, 500 mg

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Capsule, Oral:

Generic: 250 mg, 500 mg

Suspension Reconstituted, Oral:

Keflex: 125 mg/5 mL (100 mL, 200 mL); 250 mg/5 mL (200 mL)

Generic: 125 mg/5 mL (100 mL, 150 mL, 200 mL); 250 mg/5 mL (100 mL, 150 mL, 200 mL)

Tablet, Oral:

Keflex: 250 mg, 500 mg

Generic: 250 mg, 500 mg

Anatomic Therapeutic Chemical (ATC) Classification

J01DB01

Generic Available (US)

Yes

Pricing: US

Capsules (Cephalexin Oral)

250 mg (per each): $0.19 - $0.87

500 mg (per each): $0.34 - $1.97

750 mg (per each): $7.38 - $7.69

Capsules (Keflex Oral)

250 mg (per each): $10.43

500 mg (per each): $10.43

750 mg (per each): $10.43

Suspension (reconstituted) (Cephalexin Oral)

125 mg/5 mL (per mL): $0.09 - $0.24

250 mg/5 mL (per mL): $0.19 - $0.29

Tablets (Cephalexin Oral)

250 mg (per each): $4.18

500 mg (per each): $8.22

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Mechanism of Action

Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.

Pharmacodynamics/Kinetics

Absorption: Rapid (90%); delayed in young children and may be decreased up to 50% in neonates

Distribution: Widely into most body tissues and fluids, including gallbladder, liver, kidneys, bone, sputum, bile, and pleural and synovial fluids; CSF penetration is poor

Protein binding: 10% to 15%

Half-life elimination: Neonates: 5 hours; Children 3 to 12 months: 2.5 hours; Adults: 0.5 to 1.2 hours (prolonged with renal impairment)

Time to peak, serum: ~1 hour

Excretion: Urine (>90% as unchanged drug) within 8 hours

Dental Use

Prophylaxis in total joint replacement patients undergoing dental procedures; alternative oral antibiotic for prevention of infective endocarditis in individuals allergic to penicillins or ampicillin

Note: Individuals allergic to amoxicillin (penicillins) may receive cephalexin provided they have not had an immediate, local, or systemic IgE-mediated anaphylactic allergic reaction to penicillin.

* See Uses in AHFS Essentials for additional information.

Local Anesthetic/Vasoconstrictor Precautions

No information available to require special precautions

Dental Health Professional Considerations

Cephalexin is effective against anaerobic bacteria, but the sensitivity of alpha-hemolytic Streptococcus vary; approximately 10% of strains are resistant. Nearly 70% are intermediately sensitive. Patients allergic to penicillins can use a cephalosporin; the incidence of cross-reactivity between penicillins and cephalosporins is 1% to 5% when the allergic reaction to penicillin is delayed. If the patient has a history of anaphylaxis to penicillin, cephalosporins are contraindicated in these patients.

Effects on Dental Treatment

No significant effects or complications reported (see Dental Health Professional Considerations)

Effects on Bleeding

No information available to require special precautions

Dental Usual Dosing

Prophylaxis against infective endocarditis (dental, oral, or respiratory tract procedures): Oral:

Children >1 year: 50 mg/kg 30 to 60 minutes prior to procedure; maximum: 2 g

Children >15 years and Adults: 2 g 30 to 60 minutes prior to procedure

Note: American Heart Association (AHA) guidelines now recommend prophylaxis only in patients undergoing invasive procedures and in whom underlying cardiac conditions may predispose to a higher risk of adverse outcomes should infection occur.

Prophylaxis in total joint replacement patients undergoing dental procedures which produce bacteremia: Oral: Adults: 2 g 1 hour prior to procedure

Note: In general, patients with prosthetic joint implants do not require prophylactic antibiotics prior to dental procedures. In planning an invasive oral procedure, dental consultation with the patient's orthopedic surgeon may be advised to review the risks of infection.

Related Information

Index Terms

Cephalexin Monohydrate

FDA Approval Date

January 04, 1971

References

American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. Red Book: 2018 Report of the Committee on Infectious Diseases. 31st ed. Itasca, IL: American Academy of Pediatrics; 2018.

American Academy of Pediatrics (AAP) Subcommittee on Urinary Tract Infection, Steering Committee on Quality Improvement and Management. Urinary tract infection: clinical practice guideline for the diagnosis and management of the initial UTI in febrile infants and children 2 to 24 months. Pediatrics. 2011;128(3):595-610.[PubMed 21873693 ]

American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins-Obstetrics. ACOG practice bulletin no. 199: use of prophylactic antibiotics in labor and delivery. Obstet Gynecol. 2018;132(3):e103-e119.[PubMed 30134425]

American College of Obstetricians and Gynecologists (ACOG) Committee on Obstetric Practice. ACOG Committee Opinion, Number 782: Prevention of group B Streptococcal early-onset disease in newborns. Obstet Gynecol. 2019;134(1):e19-e40. doi: 10.1097/AOG.0000000000003334.[PubMed 31241599]

Amir LH, Academy of Breastfeeding Medicine Protocol Committee. ABM clinical protocol #4: Mastitis, revised March 2014. Breastfeed Med. 2014;9(5):239-243.[PubMed 24911394]

Anderson PO, Sauberan JB. Modeling drug passage into human milk. Clin Pharmacol Ther. 2016;100(1):42-52.[PubMed 27060684]

Anger J, Lee U, Ackerman AL, et al. Recurrent uncomplicated urinary tract infections in women: AUA/CUA/SUFU guideline. J Urol. 2019;202(2):282-289. doi: 10.1097/JU.0000000000000296.[PubMed 31042112]

Aronoff GR, Bennett WM, Berns JS, et al. Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children. 5th ed. Philadelphia, PA: American College of Physicians; 2007.

Autmizguine J, Watt KM, Théorêt Y, et al. Pharmacokinetics and pharmacodynamics of oral cephalexin in children with osteoarticular infections. Pediatr Infect Dis J. 2013;32(12):1340-1344.[PubMed 23811740]

Baddour LM. Impetigo. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed December 10, 2019.

Baltimore RS, Gewitz M, Baddour LM, et al. Infective endocarditis in childhood: 2015 update: a scientific statement from the American Heart Association. Circulation. 2015;132(15):1487-1515.[PubMed 26373317]

Berbari E, Baddour LM. Prosthetic joint infection. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed December 10, 2019.

Berens PD. Breast pain: engorgement, nipple pain, and mastitis. Clin Obstet Gynecol. 2015;58(4):902-914.[PubMed 26512442]

Bergan T. Pharmacokinetic Properties of Cephalosporins. Drugs, 1987;34(suppl 2):89-104.[PubMed 3319507]

Bolding OT. Clinical comparison of cefadroxil, new oral cephalosporin, and cephalexin in uncomplicated urinary tract infection. Urology. 1978;12(3):321-324. doi: 10.1016/0090-4295(78)90397-7.[PubMed 360561]

Bradley JS, Byington CL, Shah SS, et al; Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis. 2011;53(7):e25-e76.[PubMed 21880587]

Bradley JS and Nelson JD, eds. Nelson's Pediatric Antimicrobial Therapy. 25th ed. Itasca, IL: American Academy of Pediatrics; 2019.

Cephalexin (oral suspension) [prescribing information]. Parsippany, NJ: Ascend Laboratories, LLC; December 2018.

Creatsas G, Pavlatos M, Lolis D, Kaskarelis D. A study of the kinetics of cephapirin and cephalexin in pregnancy. Curr Med Res Opin. 1980;7(1):43-46.[PubMed 7428412]

Dajani AS, Taubert KA, Wilson W, et al. Prevention of Bacterial Endocarditis Recommendations by the American Heart Association. JAMA. 1997;277(22):1794-1801.[PubMed 9178793]

Gower PE. The use of small doses of cephalexin (125 mg) in the management of recurrent urinary tract infection in women. J Antimicrob Chemother. 1975;1(3)(suppl):93-98. doi: 10.1093/jac/1.suppl_3.93.[PubMed 1104559]

Griffith RS. The pharmacology of cephalexin. Postgrad Med J. 1983;59(suppl 5):16-27.[PubMed 6364086]

Hooton TM, Gupta K. Acute uncomplicated cystitis in women. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed December 10, 2019a.

Hooton TM, Gupta K. Acute uncomplicated cystitis in men. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed November 20, 2019b.

Hooton TM, Gupta K. Urinary tract infections and asymptomatic bacteriuria in pregnancy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed November 20, 2019c.

Hooton TM, Gupta K. Recurrent simple cystitis in women. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed December 18, 2019d.

Ilett KF, Hackett LP, Ingle B, Bretz PJ. Transfer of probenecid and cephalexin into breast milk. Ann Pharmacother. 2006;40(5):986-989.[PubMed 16551765]

Ito S, Blajchman A, Stephenson M, Eliopoulos C, Koren G. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. Am J Obstet Gynecol. 1993;168(5):1393-1399.[PubMed 8498418]

Ito S. Drug therapy for breast-feeding women. N Engl J Med. 2000;343(2):118-126.[PubMed 10891521]

Johnson SE, Foord RD. Cephalexin dosage in general practice assessed by double-blind trial. Curr Med Res Opin. 1972;1(1):37-48. doi: 10.1185/03007997209111143.[PubMed 4589401]

Kafetzis DA, Siafas CA, Georgakopoulos PA, Papadatos CJ. Passage of cephalosporins and amoxicillin into the breast milk. Acta Paediatr Scand. 1981;70(3):285-288.[PubMed 7246123]

Kanafani ZA. Invasive Cutibacterium (formerly Propionibacterium) infections. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed December 10, 2019.

Keflex (cephalexin) capsules [prescribing information]. Locust Valley, NY: Pragma Pharmaceuticals, LLC; December 2018.

Keflex (cephalexin) suspension [prescribing information]. Locust Valley, NY: Pragma Pharmaceuticals, LLC; December 2018.

Keflex (cephalexin) [product monograph]. Montreal, Québec: Pendopharm; May 2018.

Lieberthal AS, Carroll AE, Chonmaitree T, et al. The diagnosis and management of acute otitis media. Pediatrics. 2013;131(3):e964-e999.[PubMed 23439909 ]

Menday AP. Comparison of pivmecillinam and cephalexin in acute uncomplicated urinary tract infection. Int J Antimicrob Agents. 2000;13(3):183-187. doi: 10.1016/s0924-8579(99)00118-1.[PubMed 10724022]

Nicolle LE, Gupta K, Bradley SF, et al. Clinical practice guideline for the management of asymptomatic bacteriuria: 2019 update by the Infectious Diseases Society of America. Clin Infect Dis. 2019;68(10):e83-e110. doi: 10.1093/cid/ciy1121.[PubMed 30895288]

Osmon DR, Berbari EF, Berendt AR, et al; Infectious Diseases Society of America. Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2013;56(1):e1-e25.[PubMed 23223583]

Paterson ML, Henderson A, Lunan CB, et al, "Transplacental Transfer of Cephalexin," Clinical Medicine, 1972, 22-4.

Pedler SJ, Bint AJ. Comparative study of amoxicillin-clavulanic acid and cephalexin in the treatment of bacteriuria during pregnancy. Antimicrob Agents Chemother. 1985;27(4):508-510. doi: 10.1128/aac.27.4.508.[PubMed 4004191]

Pfau A, Sacks TG. Effective prophylaxis for recurrent urinary tract infections during pregnancy. Clin Infect Dis. 1992;14(4):810-814. doi: 10.1093/clinids/14.4.810.[PubMed 1576275]

Pichichero ME. Treatment and prevention of streptococcal pharyngitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed February 13, 2020.

Shulman ST, Bisno AL, Clegg HW, et al; Infectious Diseases Society of America. Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America [published correction appears in Clin Infect Dis. 2014;58(10):1496].Clin Infect Dis. 2012;55(10):e86-e102.[PubMed 22965026]

Sollecito TP, Abt E, Lockhart PB, et al. The use of prophylactic antibiotics prior to dental procedures in patients with prosthetic joints: Evidence-based clinical practice guideline for dental practitioners--a report of the American Dental Association Council on Scientific Affairs. J Am Dent Assoc. 2015; 146(1):11-16.[PubMed 25569493]

Stevens DL, Bisno AL, Chambers HF, et al; Infectious Diseases Society of America. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America [published correction appears in Clin Infect Dis. 2015;60(9):1448]. Clin Infect Dis. 2014;59(2):e10-e52.[PubMed 24973422]

Warady BA, Bakkaloglu S, Newland J, et al. Consensus guidelines for the prevention and treatment of catheter-related infections and peritonitis in pediatric patients receiving peritoneal dialysis: 2012 update. Perit Dial Int. 2012;32 Suppl 2:S32-86.[PubMed 22851742]

Wilson W, Taubert KA, Gewitz M, et al; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee; American Heart Association Council on Cardiovascular Disease in the Young; American Heart Association Council on Clinical Cardiology; American Heart Association Council on Cardiovascular Surgery and Anesthesia; Quality of Care and Outcomes Research Interdisciplinary Working Group. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group [published correction appears in Circulation. 2007;116(15):e376-e377]. Circulation. 2007;115(15):1736-1754.[PubMed 17446442]

World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. http://www.who.int/maternal_child_adolescent/documents/55732/en/

Wynn RL, Bergman SA, Meiller TF, et al. Antibiotics in treating oral-facial infections of odontogenic origin: an update. Gen Dent. 2001;49(3):238-40, 242, 244 passim.[PubMed 12004720]

Brand Names: International

Acelex (BD); Airex (PH); Alexin (IN); Arlexin (CR, DO, GT, HN, NI, PA, SV); Asef (BD); Avloxin (BD); Axcel (LK); Bloflex (PH); Capxin (CR, DO, GT, HN, NI, PA, SV); Cecan (PY); Cefabiotic (ID); Cefacet (FR); Cefacin-M (HK); Cefadal (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZA, ZM, ZW); Cefadin (EC); Cefadyl (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW); Cefalin (ID, PH); Cefalver (MX); Cefamor (ET, ZW); Cefastad (HK); Ceff (ET); Cefovit (IL); Cefrax (TR); Celexin (ET); Cephadar Forte (LB); Cephalen (SG); Cephalex (BH, DE); Cephalexyl (TH); Cephanmycin (MY, SG); Cephast (ET); Cephoxin (EG); Ceporex (BB, BM, BS, BZ, CR, CY, EG, GB, GT, GY, HN, IQ, IR, IT, JM, JO, KW, LB, LY, MX, NI, NZ, OM, PA, PH, PT, SA, SR, SV, SY, TT, VN, YE, ZA); Ceporex Forte (PT); Ceporexin (AR); Ceprax (CO); Ceproex (DO); Ceralin (HR); Cerexin (ZA); Erocetin (PY, UY); Falexin (KR); Farmalex (TH); Felexin (ET, LK, MY, TR); Fexin (ZA); Glexil (VN); Glopixin (VN); Ibilex (AU, NZ, TH); Inphalex (ID); Italcefal (EC); Kefacin (CY, IQ, IR, JO, KR, KW, LY, OM, SA, SY, YE); Kefalex (FI); Kefalospes (GR); Kefaxin (GR); Keflex (AE, AT, AU, BB, BF, BJ, BM, BR, BS, BZ, CI, CO, CY, DK, EE, EG, ET, GB, GH, GM, GN, GR, GY, IE, IL, JM, JO, KE, KW, LB, LI, LR, MA, ML, MR, MU, MW, MX, NE, NG, NO, PE, PH, PK, PL, PT, QA, RO, SA, SC, SD, SE, SL, SN, SR, TH, TN, TT, TZ, UG, ZM, ZW); Kefloridina (ES); Keforal (AR, BE, FR, IT, NL, VE); Kidolex (TW); Larixin (JP); LC-Lexin (PH); Lecef (LK); Lenocef (ZA); Lexin (AE, BD, JO, PE, QA); Lexipron (ID); Madlexin (ID); Meceta (VN); Medolexin (MY); Midaflex (QA); Monocef (LI); Nafacil-S (MX); Neokef (MY); Nufex (IN); Oracef (CZ); Oriphex (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW); Ospeksyn (UA); Ospexin (AT, BG, CY, CZ, EG, IQ, IR, JO, KW, LY, MY, OM, QA, SA, SY, YE); Ospexina (CO); Paferxin (MX); Palitrex (ID); Pectril (PH); Pharmexin (CY, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE); Plecef (LK); Proxicef (HR); Ramoxin (JO); Rancef (AU); Relaxin (PH); Sanaxin (AT); Sef (LI); SEF (TR); Sepexin (IN); Septilisin (AR); Servicef (MX); Servispor (TW); Sialexin (TH); Sofilex (HK, MY, SG); Solulexin (MY); Sorlex (PH); Sporicef (TH); Sporidex (AE, IN, PH); Sporidin (TH); Sporidin AF (TH); Theoflex (LK); Torlasporin (LB); Uphalexin (MY, SG); Winlex (TW); Zecef (LK); Zelexin (PH)

Last Updated 3/14/20

Google Sites

Report abuse